| Drugging an undruggable pocket on KRAS D Kessler, M Gmachl, A Mantoulidis, LJ Martin, A Zoephel, M Mayer, ... Proceedings of the National Academy of Sciences 116 (32), 15823-15829, 2019 | 388 | 2019 |
| Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer GA Hobbs, NM Baker, AM Miermont, RD Thurman, M Pierobon, TH Tran, ... Cancer discovery 10 (1), 104-123, 2020 | 167 | 2020 |
| Discovery of 2-indole-acylsulfonamide myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods NF Pelz, Z Bian, B Zhao, S Shaw, JC Tarr, J Belmar, C Gregg, ... Journal of medicinal chemistry 59 (5), 2054-2066, 2016 | 154 | 2016 |
| Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer CM Goodwin, OW Rossanese, ET Olejniczak, SW Fesik Cell Death & Differentiation 22 (12), 2098-2106, 2015 | 118 | 2015 |
| Discovery of tricyclic indoles that potently inhibit Mcl-1 using fragment-based methods and structure-based design JP Burke, Z Bian, S Shaw, B Zhao, CM Goodwin, J Belmar, CF Browning, ... Journal of medicinal chemistry 58 (9), 3794-3805, 2015 | 105 | 2015 |
| Low-dose vertical inhibition of the RAF-MEK-ERK cascade causes apoptotic death of KRAS mutant cancers I Ozkan-Dagliyan, JN Diehl, SD George, A Schaefer, B Papke, ... Cell reports 31 (11), 2020 | 85 | 2020 |
| Discovery and biological characterization of potent myeloid cell leukemia‐1 inhibitors T Lee, Z Bian, B Zhao, LJ Hogdal, JL Sensintaffar, CM Goodwin, J Belmar, ... FEBS letters 591 (1), 240-251, 2017 | 66 | 2017 |
| Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer CM Goodwin, AM Waters, JE Klomp, S Javaid, KL Bryant, CA Stalnecker, ... Cancer research 83 (1), 141-157, 2023 | 54 | 2023 |
| Concurrent inhibition of IGF1R and ERK increases pancreatic cancer sensitivity to autophagy inhibitors CA Stalnecker, KR Grover, AC Edwards, MF Coleman, R Yang, ... Cancer research 82 (4), 586-598, 2022 | 36 | 2022 |
| Potential of chromium (III) picolinate for reproductive or developmental toxicity following exposure of male CD-1 mice prior to mating DA McAdory, NR Rhodes, F Briggins, MM Bailey, KR Di Bona, C Goodwin, ... Biological trace element research 143, 1666-1672, 2011 | 27 | 2011 |
| CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment JE Klomp, YS Lee, CM Goodwin, B Papke, JA Klomp, AM Waters, ... Cell reports 37 (9), 2021 | 23 | 2021 |
| Functional and biological heterogeneity of KRASQ61 mutations MV Huynh, GA Hobbs, A Schaefer, M Pierobon, LM Carey, JN Diehl, ... Science signaling 15 (746), eabn2694, 2022 | 20 | 2022 |
| Electronarcosis produced by a combination of direct and alternating current. A preliminary study: 1. apparatus and electrodes RH Smith, C Goodwin, E Fowler, GW Smith, PP Volpitto The Journal of the American Society of Anesthesiologists 22 (2), 163-168, 1961 | 20 | 1961 |
| Targeting p130Cas-and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition AM Waters, TO Khatib, B Papke, CM Goodwin, GA Hobbs, JN Diehl, ... Cell reports 35 (13), 2021 | 19 | 2021 |
| Reply to Tran et al.: Dimeric KRAS protein–protein interaction stabilizers D Kessler, A Gollner, M Gmachl, A Mantoulidis, LJ Martin, A Zoephel, ... Proceedings of the National Academy of Sciences 117 (7), 3365-3367, 2020 | 15 | 2020 |
| Concurrent inhibition of ERK and farnesyltransferase suppresses the growth of HRAS mutant head and neck squamous cell carcinoma S Javaid, A Schaefer, CM Goodwin, VV Nguyen, FL Massey, M Pierobon, ... Molecular cancer therapeutics 21 (5), 762-774, 2022 | 13 | 2022 |
| Vertical Inhibition of the RAF–MEK–ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant … N Garcia, V Del Pozo, ME Yohe, CM Goodwin, TJ Shackleford, L Wang, ... Molecular cancer therapeutics 21 (1), 170-183, 2022 | 12 | 2022 |
| Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer JN Diehl, PS Hibshman, I Ozkan-Dagliyan, CM Goodwin, SV Howard, ... Advances in Cancer Research 153, 101-130, 2022 | 11 | 2022 |
| Defining the KRAS-and ERK-dependent transcriptome in KRAS-mutant cancers JA Klomp, JE Klomp, CA Stalnecker, KL Bryant, AC Edwards, ... Science 384 (6700), eadk0775, 2024 | 6 | 2024 |
| Detection of phenotype‐specific therapeutic vulnerabilities in breast cells using a CRISPR loss‐of‐function screen A Barkovskaya, CM Goodwin, K Seip, B Hilmarsdottir, S Pettersen, ... Molecular Oncology 15 (8), 2026-2045, 2021 | 5 | 2021 |
